Nijhawan Pardeep 4

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 82,236 restricted share units (RSUs) on 2026-02-19. The RSUs were reported as acquired at $0.00 and vested in full upon grant. According to the filing, these RSUs were awarded in lieu of a portion of the CEO’s cash bonus earned for the calendar year ended December 31, 2025.

Key Details

• Transaction date: 2026-02-19; Grant/award (Code A) of 82,236 RSUs at $0.00 per share (acquisition value $0).
• Filing date: 2026-03-02 (filed 11 days after the transaction date), which is later than the typical 2-business-day Form 4 deadline.
• Shares owned after the transaction: not specified in the information provided in this summary.
• Footnotes of note:
  • F1: RSUs vested in full upon grant under the Issuer’s 2019 Equity Incentive Compensation Plan; awarded in lieu of part of the 2025 cash bonus.
  • F2 & F3: Some reported shares are held through entities and a family trust wholly or co-controlled by the reporting person; the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Context

• RSUs are equity awards that convert to shares upon vesting; because these RSUs vested immediately, the reporting person effectively received shares rather than an option that must be exercised.
• Awards issued in lieu of cash bonuses are a common compensation mechanism and do not necessarily signal a buy or sell preference by the insider.
• The late filing may reflect a reporting delay; while important for compliance, a late Form 4 alone is not a direct indicator of company fundamentals.